LEHNE-PHARM-006 – INDIVIDUAL VARIATION IN
DRUG RESPONSES EXAM LATEST 2026-2027 UPDATE
100+ QUESTIONS AND ANSWERS WITH RATIONALES
1. The primary determinant of the intensity of a drug response is:
A. Route of administration
B. Drug concentration at the site of action
C. Drug brand
D. Patient diet
Rationale: Drug effect intensity depends mainly on concentration at
receptor sites; higher concentration produces stronger effects.
2. Which patient population is most sensitive to standard drug doses?
A. Young adults
B. Adolescents
C. Infants and older adults
D. Middle-aged adults
Rationale: Infants have immature organs and older adults have declining
organ function.
3. Dosage adjustments for body size are most accurately based on:
A. Body weight only
B. Height
C. Body surface area (BSA)
D. BMI alone
Rationale: BSA better reflects fat distribution and drug distribution than
weight alone.
4. In renal disease, drug toxicity occurs mainly because of:
A. Increased metabolism
B. Increased absorption
C. Reduced drug excretion and accumulation
, D. Increased protein binding
Rationale: Kidney disease decreases elimination, increasing drug levels.
5. Liver disease affects drug response primarily by:
A. Increasing absorption
B. Decreasing drug metabolism
C. Increasing receptor sensitivity
D. Increasing excretion
Rationale: Impaired hepatic metabolism leads to drug accumulation.
6. Acid-base imbalance affects drug response mainly by altering:
A. Drug packaging
B. Ionization and distribution of drugs
C. Drug taste
D. Drug color
Rationale: pH changes affect ionization, influencing absorption and
distribution.
7. Hypokalemia increases toxicity risk with:
A. Digoxin
B. Insulin
C. Heparin
D. Morphine
Rationale: Low potassium enhances digoxin’s cardiac toxicity.
8. Pharmacodynamic tolerance is best defined as:
A. Faster drug excretion
B. Receptor-level adaptation reducing drug response
C. Increased absorption
D. Allergic reaction
Rationale: Receptors down-regulate or become less responsive over time.
9. Metabolic tolerance occurs due to:
A. Receptor blockade
B. Enzyme induction increasing drug metabolism
, C. Reduced absorption
D. Decreased blood flow
Rationale: Liver enzymes break down drugs faster, lowering effect.
10.Tachyphylaxis is:
A. Gradual tolerance over months
B. Rapid loss of drug effect after repeated dosing
C. Permanent immunity to drugs
D. Allergy reaction
Rationale: Happens quickly due to depletion of mediators or receptors.
11.The placebo effect is:
A. Toxic drug reaction
B. Response caused by patient expectation rather than drug action
C. Drug allergy
D. Drug overdose
Rationale: Psychological expectations influence perceived or actual
response.
12.Bioavailability refers to:
A. Drug cost
B. Drug color change
C. Amount of drug reaching systemic circulation
D. Drug shelf life
Rationale: It determines how much active drug is available in blood.
13.Genetic variability in drug response is studied in:
A. Pharmacokinetics
B. Toxicology
C. Pharmacogenomics
D. Pathology
Rationale: Pharmacogenomics examines genetic influence on drug response.
14.CYP2D6 deficiency affects:
A. Warfarin activation
DRUG RESPONSES EXAM LATEST 2026-2027 UPDATE
100+ QUESTIONS AND ANSWERS WITH RATIONALES
1. The primary determinant of the intensity of a drug response is:
A. Route of administration
B. Drug concentration at the site of action
C. Drug brand
D. Patient diet
Rationale: Drug effect intensity depends mainly on concentration at
receptor sites; higher concentration produces stronger effects.
2. Which patient population is most sensitive to standard drug doses?
A. Young adults
B. Adolescents
C. Infants and older adults
D. Middle-aged adults
Rationale: Infants have immature organs and older adults have declining
organ function.
3. Dosage adjustments for body size are most accurately based on:
A. Body weight only
B. Height
C. Body surface area (BSA)
D. BMI alone
Rationale: BSA better reflects fat distribution and drug distribution than
weight alone.
4. In renal disease, drug toxicity occurs mainly because of:
A. Increased metabolism
B. Increased absorption
C. Reduced drug excretion and accumulation
, D. Increased protein binding
Rationale: Kidney disease decreases elimination, increasing drug levels.
5. Liver disease affects drug response primarily by:
A. Increasing absorption
B. Decreasing drug metabolism
C. Increasing receptor sensitivity
D. Increasing excretion
Rationale: Impaired hepatic metabolism leads to drug accumulation.
6. Acid-base imbalance affects drug response mainly by altering:
A. Drug packaging
B. Ionization and distribution of drugs
C. Drug taste
D. Drug color
Rationale: pH changes affect ionization, influencing absorption and
distribution.
7. Hypokalemia increases toxicity risk with:
A. Digoxin
B. Insulin
C. Heparin
D. Morphine
Rationale: Low potassium enhances digoxin’s cardiac toxicity.
8. Pharmacodynamic tolerance is best defined as:
A. Faster drug excretion
B. Receptor-level adaptation reducing drug response
C. Increased absorption
D. Allergic reaction
Rationale: Receptors down-regulate or become less responsive over time.
9. Metabolic tolerance occurs due to:
A. Receptor blockade
B. Enzyme induction increasing drug metabolism
, C. Reduced absorption
D. Decreased blood flow
Rationale: Liver enzymes break down drugs faster, lowering effect.
10.Tachyphylaxis is:
A. Gradual tolerance over months
B. Rapid loss of drug effect after repeated dosing
C. Permanent immunity to drugs
D. Allergy reaction
Rationale: Happens quickly due to depletion of mediators or receptors.
11.The placebo effect is:
A. Toxic drug reaction
B. Response caused by patient expectation rather than drug action
C. Drug allergy
D. Drug overdose
Rationale: Psychological expectations influence perceived or actual
response.
12.Bioavailability refers to:
A. Drug cost
B. Drug color change
C. Amount of drug reaching systemic circulation
D. Drug shelf life
Rationale: It determines how much active drug is available in blood.
13.Genetic variability in drug response is studied in:
A. Pharmacokinetics
B. Toxicology
C. Pharmacogenomics
D. Pathology
Rationale: Pharmacogenomics examines genetic influence on drug response.
14.CYP2D6 deficiency affects:
A. Warfarin activation
